Healthcare’s Once-in-a-Generation Disruption
The cost of healthcare in the United States continues to rise and the availability continues to decline. Healthcare spending accounts for 18% of U.S. GDP, and the costs in the U.S. are the highest in the world, increasing 130% in just the last decade. With this complexity comes an opportunity for entrepreneurs, innovators, and investors. iSelect is focused on finding technologies and innovations that reduce costs, increase accessibility, and improve quality of care.
iSelect Portfolio Companies
iSelect focuses on early-stage healthcare companies that are poised to help push the next healthcare revolution forward. We deliberately invest in companies that can make a positive impact on our society, as well as on the bottom line.
Location: Cambridge, MA
Prior Round Funding: Seed
Location:
Prior Round Funding:
Cocoon Biotech is a biomaterials company that uses fibroin, a protein derived from the cocoon of the silkworm, to both replace unsustainable ingredients and provide the foundation for a new generation of innovative products.
Location: St. Louis, MO
Prior Round Funding: Series B
Location:
Prior Round Funding:
Cofactor Genomics is a precision medicine company that focuses on RNA for its understanding of disease – initially cancer but with applicability across many diseases.
Location: Seattle, WA
Prior Round Funding: Series B
Location:
Prior Round Funding:
Cyrus Biotechnology is a drug discovery company that has developed and is employing innovative protein design software to make highly differentiated therapeutics. The company is building both internal and partnered protein biologics that are engineered to be safer, longer lived, more efficacious and more readily manufactured than those currently available.
Location: Germantown, TN
Prior Round Funding: Series B
Location:
Prior Round Funding:
Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis. Their first product is used to predict post operative ileus after GI surgeries.
Location: St. Louis, MO
Prior Round Funding:
Location:
Prior Round Funding:
Euclises Pharmaceuticals is developing novel enzyme (COX-2) inhibitors designed to increase the effectiveness of chemotherapy safely
Location: San Francisco, CA
Prior Round Funding: Series A
Location:
Prior Round Funding:
Combines known cancer therapies with targeted and specific nutritional interventions to improve the outcome of many cancers
Location: Minneapolis, MN
Prior Round Funding: Series D
Location:
Prior Round Funding:
Flywheel offers a SaaS platform that provides cloud-scale data management and computational analysis.
Location: Saint Louis, MO
Prior Round Funding: Series B
Location:
Prior Round Funding:
Geneoscopy is developing next generation diganostics that use stool-derived RNA to prevent, detect, and guide treatment for gastrointestinal diseases.
Location: Minneapolis, MN
Prior Round Funding: Series C
Location:
Prior Round Funding:
GeneMatters is a digital health platform that provides scalable, on-demand genetic counseling to meet the rapidly growing demand for genetic services.
Location: Minneapolis, MN
Prior Round Funding: Series A
Location:
Prior Round Funding:
Gila Therapeutics is developing a treatment for obesity using naturally occurring hormones known to induce satiety, leading to weight loss.
Location: Seattle, WA
Prior Round Funding: Series A
Location:
Prior Round Funding:
Healionics, Inc. has developed a novel bio-material called STAR, that features strong anti-infective properties and significant reduction in the formation of scar tissue around implanted medical devices coated with the material.
Location: Palo Alto, CA
Prior Round Funding: Seed
Location:
Prior Round Funding:
HepaTx is a cell therapy company developing stem cell technologies to produce low-cost and scalable sources of liver cells that can be used to preserve or regenerate liver function in patients with liver failure.
Location: Cambridge, MA
Prior Round Funding: Series A
Location:
Prior Round Funding:
Holobiome is developing a platform for microbiome-based therapeutics to treat diseases of the central and enteric nervous systems.
Location: St. Louis, MO
Prior Round Funding: Series B
Location:
Prior Round Funding:
Immunophotonics has developed a novel polymer that retains cancer antigens after an ablation procedure. Injected into the tumor site after the procedure, it primes the immune system for a systemic wide response to the tumor and its metastases.
Location: Davis, CA
Prior Round Funding: Series D
Location:
Prior Round Funding:
Evolve Biosystems is an infant nutrition that develops microbial products that are key to the development of gut & immune health.
Location: New York, NY
Prior Round Funding: Series A
Location:
Prior Round Funding:
Mend is a health & nutrition startup focused on delivering nutritional & digital interventions that improve patient recovery and accelerate the adoption of healthy lifestyle choices.
Location: Natick, MA
Prior Round Funding: Series A
Location:
Prior Round Funding:
Mercy BioAnalytics is on a mission to save lives through the early detection of cancer. Their patented approach analyzes extracellular vesicles and shows promise in offering a highly sensitive screening test for early-stage cancers.
Location: Exton, PA
Prior Round Funding: Series A
Location:
Prior Round Funding:
MOBILion Systems is an analytical instrumentation company using ion mobility to substantially improve the ability to see and identify previously undetectable, clinically significant molecules in minutes.
Location: San Diego, CA
Prior Round Funding: Series B2
Location:
Prior Round Funding:
Molecular Assemblies is developing an enzymatic DNA synthesis platform technology. Molecular Assemblies’ novel enzymatic DNA synthesis platform has the potential to fundamentally transform how we write genetic building blocks with applications across food, healthcare, energy, and beyond.
Location: Willoughby Hills, OH
Prior Round Funding: Series C
Location:
Prior Round Funding:
Neuros Medical, a medical device company, develops an electrical nerve block to treat chronic pain for conditions including neuroma/residual limb pain and chronic post-surgical pain.
Location: Boston, MA
Prior Round Funding: Series A
Location:
Prior Round Funding:
Nix Biosensors is developing a wearable device and biosensor system platform that monitors hydration in real-time, helping reduce health incidents associated with dehydration while improving performance for athletes, laborers, military personnel and the elderly.
Location: Davis, CA
Prior Round Funding: Series A
Location:
Prior Round Funding:
One.Bio (formerly BCD Bioscience) discovers, develops and understands naturally occurring carbohydrate based prebiotics that enable unprecedented control of the microbiome for beneficial health and nutritional outcomes.
Location: Berkeley, CA
Prior Round Funding: Series A
Location:
Prior Round Funding:
High efficiency continuous fermentation platform for biomanufacturing that decouples growth and production, solving the problems of contamination and genetic drift
Location: St. Louis, MO
Prior Round Funding: Seed
Location:
Prior Round Funding:
Readout (or The Company) has developed a low-cost breath-analysis device with clinical grade accuracy for measuring blood-ketone levels, an important indicator of a patient’s metabolism.
Location: Burlingame, CA
Prior Round Funding: Series A
Location:
Prior Round Funding:
SciBac is developing a platform technology called MERGE that enables the Company to efficiently combine desired traits of two microbes into one stable hybrid organism through lab-induced directed evolution.
Meet Our Selection Committee
Our Healthcare Selection Committee consists of industry and subject matter experts who help guide iSelect’s investment decisions. With firsthand experience and a true pulse on the industry, we consider these individuals key to our success in finding and investing in healthcare innovation.
Ruchir Sehra, M.D., is a medtech executive with extensive experience in early (private), mid (public), and late stage (acquisition) medical device companies in various health and disease areas. Dr. Sehra currently serves as the CEO…
Surekha Trivedi is VP Strategic Development at Danaher. She is a Senior Strategy, M&A, and Product Development Executive with a deep understanding of the life sciences, diagnostics, and healthcare markets. Recognized as a strategy expert…
Jill Davies is Co-Founder and Chief Executive Officer for GeneMatters. Jill has more than 20 years’ experience in the genetics field, with leadership in clinical services, telehealth, product development, business development and operations. Prior to…
Vice President of Research at Matatu, Nathan McNulty is microbiologist with a passion for addressing complex problems in healthcare, nutrition, and agriculture using innovative technologies, carefully conducted science, and teamwork.
Emily Fassi is a board-certified genetic counselor with experience counseling adults and children about genetic diagnoses and predisposition to genetic conditions. She currently works at the Mountain States Tumor Institute with patients who have a…
Dr. David Messina has spent the last 20 years in computational biology and genetics. He worked on the Human Genome Project at Washington University in Saint Louis, mapped disease genes at the University of Chicago,…
Dr. Bruce German is a Professor and Chemist of Food Science and Technology at the University of California, Davis and researches the role of fats and other components in the diet. He develops ways to…
A regulatory professional with over 27 years of experience in the medical products industry, Melissa currently serves as Founder, President and CTO at Graematter, Inc. and Senior VP Regulatory at Topera. Specialties include regulatory intelligence research and reporting,…
Andy Daniels is a seasoned business executive and successful entrepreneur, an active angel investor, and serves on multiple governing boards with companies in the areas of venture capital, wealth management, agriculture, healthcare, technology innovation, commodity…
Dr. Paul D. Olivo, M.D., Ph.D., has been the Chief Scientific Officer of Apath, LLC since 2000 and served as its President. Dr. Olivo is an Entrepreneur-in-Residence at BioGenerator, where he previously served as a…
Bobby Sandage is currently President and CEO of Euclises, Chairman of the Board of Immunophotonics, member of the board of directors of EDIS, and a member of the Cultivation Capital life sciences fund investment committee. He was…
Gian Cavallini oversees the development and execution of Advanced ICU Care’s medical staffing growth strategy and leads the implementation of various initiatives to position the company for continued growth. His expertise in development and operations,…
Presently leading Arch Cancer Care as Medical Director, Dr. Beat is a local expert in collaborative prostate cancer management. At a national level, he contributes to physician leadership committees within the US Oncology Network. Having earned an executive…
Mr. Beuttenmuller possesses over 30 years experience in Corporate Finance with Emerson Electric, Esse Health, Essence Healthcare and Innovare. He is experienced in financial analysis, risk management, mergers and acquisitions, new business development, start-ups, strategic…
Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation at UUniversity of Iowa Roy J. and Lucille A. Carver College of Medicine and former Professor of Medicine and Genetics at Washington University…
Dr. John Talley, Chief Science Officer for Euclises Pharmaceuticals and SARmont, brings over thirty years experience and a record as one of the world’s most successful medicinal chemists. He is best known as the co-inventor…
Dr. Rutter is founder and CEO of Metaphase Design Group, a design firm serving industrial, commercial and consumer product and packaging clients internationally. He is an acknowledged specialist in ergonomic product design and a leading…
Mark has served as ProteoSense’s CEO since 2013. Previously, Mark served as CEO/COO of several startups, including Assurex Health (2006-09). Mark earned a B.S. in Electrical Engineering from the Univ. of Dayton and an M.S….
Before joining OTMIR in 2016, Brian Buntaine worked for more than 15 years in the life sciences industry. He began his career as a lab manager at Washington University in St. Louis. In 2003, Brian joined…
Edwards was employed for 42 years in the pharmaceutical and life sciences arenas. From 1990 to 2010, he held Regulatory Affairs positions of increasing responsibility at TAP/Takeda Global Research & Development Center, Lake Forest, Illinois. …
Michael Nichols, Ph.D. presently serves as an investor and C level management for various startups. He serves as an Analyst for Vinlogx, a platform that acquires, stores, and analyses internal vehicle information enabling solutions across…
David Christenson joined BioGenerator as an Entrepreneur-in-Residence in 2015 focusing primarily on healthcare and specifically in information technology, care delivery and payment, and services. Over a 30-year career, David has developed a substantive background in…
An accomplished senior executive with start-ups, growth, and turn-around organizations, Renato developed a healthcare technology corporation, HealthTech Solutions, from a small start-up of 3 people to a national provider of technical solutions to health care…
Resources and News
RNA Is Becoming the New DNA, Opening New Doors in Medicine
If a person’s DNA is the roadmap of their lifetime health, their RNA is more of a real-time barometer, recording what happens in their body on a minute-by-minute basis. Our DNA stores and transfers genetic information, but remains little changed throughout our lives. At best, it can tell us about the probability we will someday develop various diseases — whether or not we will get cancer, for instance, or be susceptible to diabetes or heart disease — but it can’t tell us much about our current health.
Flywheel: Accelerating Discoveries By Creating an App Store for Science
Flywheel is building an archive of scientific developments, methods and tools so that future researchers will be able to build on those discoveries.
GeneMatters: How Genetic Testing Is Pushing Us Toward Medicine’s Next Frontier
Genetic testing has gone mainstream — consider examples like 23andMe and even Ancestry.com, which both offer genetic analysis by mail — and the market is on track to exceed $10 billion in the next several years.
![[PODCAST] Cofactor Genomics and the Future of Personalized Medicine](https://www.iselectfund.com/wp-content/uploads/2017/11/Cofactor_Genomics_Lobby-1080x675.jpg)
[PODCAST] Cofactor Genomics and the Future of Personalized Medicine
On today's podcast, Cofactor Genomics COO, Dr. David Messina discusses how his company is working to make personalized medicine a reality by focusing on the potential of RNA as a diagnostic tool. Unlike DNA, which is set in stone at birth, our RNA changes on a...
Gila Therapeutics Completes Phase I Clinical Trial
Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help...
Innovation Anarchy: Doctor, Please Stop, You’re Killing Me!
I learned three important lesson about innovation early in my career as an engineer at McDonnell Douglas. It was 1989 and I was assigned to work on the Navy’s F/A-18 Hornet, a carrier-based fighter jet. Originally designed in 1976, the F/A-18 was planned to remain...
iSelect Portfolio: Neuros Medical Closes $20 Million Funding Round
Neuros Medical, part of the iSelect healthcare portfolio since 2016, closed a $20 million Series AA financing round, led by U.S. Venture Partners and joined by iSelect, Boston Scientific, Aperture Venture Partners, Osage University Partners, and JumpStart, Inc. Neuros...
Resistant Hypertension: Ending the Death Sentence
Physicians have been fascinated with blood and the circulatory system for hundreds of years. Records dating back to early Roman times prove that bloodletting was in wide use as a treatment for disease at least 2,000 years ago, and leeches have been used in medicine...
Cofactor Genomics: RNA Is About to Make Personalized Medicine a Reality
By David Messina, PhD This is an amazing time to be in biology. In fact, I like to say that right now we’re in a place that’s a lot like where personal computers were in 1987. In those days, PCs were pretty limited in what they could do. They still ran off of floppy...
Immunophotonics, SAKK Move Forward with Research Collaboration
Cancer care is entering a new age, transitioning from treatments that attack both cancerous and healthy cells at the same time, to more targeted, specialized therapies that address the root cause of cancer itself without damaging surrounding tissues. Biotech company...
Gila Therapeutics: New Solutions for the Obesity Crisis
Obesity is the single largest health crisis facing the world today. More than one billion people worldwide are overweight or obese, accounting for 38% of the population. In the U.S., a full 68% of adults, or some 200 million people, are overweight. On average, obese...
House Calls Are Back: How Epharmix Is Revolutionizing Healthcare
There is massive consolidation occurring in the healthcare space right now, and as a result hospital systems are acting almost like private equity groups. They're sucking up all of these once-independent primary care providers and are distributing all of the...